Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review)

Mol Med Rep. 2014 May;9(5):1533-41. doi: 10.3892/mmr.2014.2040. Epub 2014 Mar 11.

Abstract

Activated monoamine oxidase (MAO) has a critical role in the pathogenesis of Alzheimer's disease (AD), including the formation of amyloid plaques from amyloid β peptide (Aβ) production and accumulation, formation of neurofibrillary tangles, and cognitive impairment via the destruction of cholinergic neurons and disorder of the cholinergic system. Several studies have indicated that MAO inhibitors improve cognitive deficits and reverse Aβ pathology by modulating proteolytic cleavage of amyloid precursor protein and decreasing Aβ protein fragments. Thus, MAO inhibitors may be considered as promising therapeutic agents for AD.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / enzymology
  • Alzheimer Disease / pathology
  • Animals
  • Blood Platelets / enzymology
  • Brain / drug effects
  • Brain / enzymology
  • Enzyme Activation
  • Humans
  • Molecular Targeted Therapy
  • Monoamine Oxidase / metabolism
  • Monoamine Oxidase Inhibitors / pharmacology
  • Monoamine Oxidase Inhibitors / therapeutic use*
  • Nerve Degeneration / enzymology
  • Neurofibrillary Tangles / enzymology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Plaque, Amyloid / enzymology

Substances

  • Monoamine Oxidase Inhibitors
  • Neuroprotective Agents
  • Monoamine Oxidase